



**Life Science 2020 Real Estate Development Symposium
October 23, 27 and 29, 2020**

Program Partner

NYC EDC

Media Partners

Genetic Engineering & Biotechnology News
Commercial Observer

Association Partners

Life Sciences Summit
Center for Biotechnology

Silver Sponsors

EWHowell
Shawmut
Skanska

Schneider Electric
Simone Development

Founding Members

Nancy J Kelley + Associates
Jaros, Baum & Bolles
Hunter Roberts Construction Group

Fried Frank
Sabey

Corporate Members

SGA
Venable LLP
Turner
Lendlease
Ennead
Cerami
HiberCell
LPE Management Services
Triumvirate Environmental
Simone Healthcare Development
Mitchell Giurgola
WSP
Loring Engineering

Skanska
Gensler
Perkins&Will
LongFellow
AKRF
DPR Construction
Langan
Anchin
Group PMx
Life Sciences Summit
Center for Biotechnology
Bioldea
EisnerAmper



Symposium Steering Committee



Mitchel W. Simpler, PE, Managing Partner, Jaros, Baum & Bolles

Mitchel Simpler joined Jaros, Baum & Bolles, one of New York's premier consulting engineering firms, in 1977, and has served as its Managing Partner since 2012. He has acted as Project Manager and Partner-in-Charge on life/health science institutions, healthcare facilities, high-rise office buildings, museums, residential and mixed-use buildings as well as hotels.

Mr. Simpler's list of notable projects in the life science sector spans the past 35 years, including premier laboratory facilities and research centers in New York City, such as the New York Genome Center; the Mount Sinai Hess Center for Science and Medicine; Weill Cornell Medical College's Belfer Research Building; MSKCC's new Memorial Inpatient Hospital, David H. Koch Center for Cancer Care, Rockefeller Research Laboratories, and viral vector and pathology laboratories; Cornell University's Biotechnology Building; Columbia University's Center for Disease Prevention and the Manhattanville campus's Jerome L. Greene Science Center; and NYU Langone Health's Smilow Research Building, Medical Science Building, and Skirball Institute of Biomolecular Medicine. His experience extends around the world to China, with the Innovation Center at Duke Kunshan University in Kunshan and the Rohm & Haas Research Center in Shanghai.

He is a licensed Professional Engineer in the State of New York and is Chair-Elect of the American Council of Engineering Companies (ACEC). He is a founding member of the Life Sciences Symposium Steering Committee.



Nancy J. Kelley, JD/MPP, President and CEO, Nancy J. Kelley + Associates

Nancy J. Kelley, President and CEO of Nancy J. Kelley & Associates, is a nationally recognized executive and lawyer who has driven key strategic initiatives in science and medicine for over twenty years.

Nancy J. Kelley + Associates (NJK+A) builds things that matter for science and medicine in order to solve some of the world's most intractable problems.


Whether advancing translational genomic research that has the potential to cure human disease and improve quality of life or facilitating ways that we can feed, fuel and heal the world through technological innovation in biology, NJK+A is committed to delivering scientific and medical breakthroughs. www.nancyjkelley.com

Ms. Kelley was the Founding Executive Director of the New York Genome Center. From its establishment in 2010 by its 11 Institutional Founding Members, she led the Center from a start-up to a fully operational, world class genomics research center and provider of cutting edge sequencing and bioinformatics services, raising \$110 million to do so.



Her prior leadership history includes work in scientific institutions, life science companies, and life science real estate development. She has overseen major development projects for clients such as the National Institutes of Health, Johns Hopkins University, the Massachusetts Institute of Technology and Boston University/ Boston Medical Center. She also led the site selection and build out for the 173,00 sq ft facility of the New York Genome Center.

Ms. Kelley currently serves or has served on boards for the New York Genome Center, The Jackson Laboratory, Beth Israel Deaconess Medical Center, and the Whitehead Institute. Earlier in her career, Ms. Kelley was appointed a White House Fellow and Truman Scholar. She holds a BA in Economics from Yale College, a JD from Harvard Law School, and a MPP from the Harvard Kennedy School.



Jonathan L. Mechanic, JD, Chairman Real Estate Department, Fried Frank

Jonathan L. Mechanic is chairman of Fried Frank's Real Estate Department. He first joined the Firm in 1978 and became a partner in 1987, when he rejoined the Firm after acting as general counsel and a managing director of developer HRO International Ltd. Mr. Mechanic routinely counsels developers, owners, investors, REITs, and lenders in all aspects of commercial real estate

transactions.

Mr. Mechanic has taught the real estate transactions course at Harvard Law School for nearly ten years. He also lectures regularly for NYU Law School, the Real Estate Board of New York and the Practising Law Institute, and is a co-author of *The Commercial Office Lease Handbook* published by the American Bar Association. Mr. Mechanic is a member of the Board of New York University School of Law and Chairman of the Advisory Board of the New York University Furman Center for Real Estate and Urban Policy.

Mr. Mechanic was recently awarded the 2016 Distinguished Alumnus Award from New York University and the 2016 Chambers USA Outstanding Contribution to the Legal Profession Award. For a decade, Mr. Mechanic has been recognized by Chambers USA as a "Star Individual" in real estate. He is consistently included on Commercial Observer's "Power 100" list of the most powerful people in New York real estate and was the only practicing attorney to make the list in 2016 and 2017.

Mr. Mechanic received his JD from New York University School of Law in 1977, where he served as an editor of the Law Review and was elected to the Order of the Coif, and his BA, magna cum laude, from Brandeis University in 1974.



James McKenna, Co-Founder, Hunter Roberts Construction Group


James C. McKenna is a co-founder of Hunter Roberts Construction Group and is responsible for leading Hunter Roberts to the forefront of the construction industry. As president and CEO, he is responsible for establishing and maintaining the quality of individualized services delivered to our clients.

He has set precedents for hands-on management and senior-level involvement in our clients' projects as well as a high standard of excellence for all Hunter Roberts employees, particularly in regards to working safely. He has created a company that is small enough to quickly respond to our clients' needs with flexible, forward thinking solutions, yet large enough to attract some of the best talent in the construction industry.

Jim is a civil engineer and a talented builder with extensive experience in the Metropolitan New York area. With his extensive construction expertise, he welcomes every construction challenge with a creative solution.

Under Jim's exceptional leadership qualities and building skills, Hunter Roberts has quickly positioned itself to adapt to market trends and demands and is a leader in many markets, including: life science, healthcare, laboratories, residential, mixed-use developments, commercial, higher education, K-12, public sector (Federal, state and local), hospitality, interiors, sports, transportation, landmark preservation, and cultural.

Hunter Roberts has served as the construction manager on several successful life sciences and laboratory projects including the New York Genome Center, New York Stem Cell Foundation Lab Fit-Out, BioBAT renovation and infrastructure upgrades as well as provided construction services to many of our finest healthcare institutions.



John Sabey, CEO, Sabey Corporation

As CEO of Sabey Corporation (Sabey), John Sabey heads up a company of 150 driven people in the acquisition and development of a commercial real estate portfolio comprising primarily office and medical technology space. The portfolio consists of approximately 5.4 million square feet developed, owned and managed by Sabey.

Sabey has long developed specialty technology properties for the medical/life sciences, communications, government, and military sectors. As Big Data emerges as an essential component of hyper-scaled products and services, the company's leadership has been quick to realize their critical reliance on robust, highly reliable data centers.

As Executive Director of Sabey Data Centers, one of the world's largest, privately-owned designer/builder/operator data center companies, Mr. Sabey has helped to assemble an enviable customer portfolio that includes globally-known enterprises in financial services, content delivery, life science research, entertainment, technology innovation and health care.



In 1995, after a successful career in Chicago with Prudential Real Estate Investors, Mr. Sabey joined the family business. He holds a BA from the University of Notre Dame and an MBA from Northwestern's Kellogg Graduate School of Management.

Speakers Headshot and Bios
(in order of appearance)

DAY ONE: OCTOBER 23RD, 2020

9:00 – 9:15 Welcome & Overview of The Meeting

Mitchel W. Simpler, PE, NYC Builds Bio+ Steering Committee, Managing Partner,
Jaros, Baum & Bolles

Nancy J Kelley, NYC Builds Bio+ Steering Committee, President and CEO, **Nancy J Kelley + Associates**

9:15 – 9:45 The Endless Frontier Act: Catalyzing U.S. Innovation Through Investment In The Discovery, Creation And Commercialization Of Frontier Technologies That Will Build The Industries Of The Future



Honorable Charles E. Schumer, United States Senator for New York

U.S. Senator Charles Ellis “Chuck” Schumer has dedicated his career to being a tireless fighter for New York. He visits all 62 counties every year and has delivered countless large and small victories across the state, including delivering \$20 billion to rebuild after the 9-11 terror attacks and passing a \$63 billion relief package to help New York recover from Superstorm Sandy. From massive snowstorms in Western New York to numerous floods across Upstate, Sen. Schumer has been there to deliver

aid and support to New Yorkers in their time of need.

From authoring a permanent tax credit to offset the rising costs of college tuition, protecting Social Security and Medicare to encouraging job-creating infrastructure projects, Senator Schumer has made it a hallmark of his career to protect the middle class and those working to reach it – including finding common sense solutions to national issues.

Chuck was born and raised in Brooklyn, NY, where his dad owned a small exterminating business and his mom was a housewife. He attended public school and graduated from James Madison High School before heading to Harvard University, and then Harvard Law School.

Chuck has two daughters, Jessica and Alison, and he still resides in Brooklyn with his wife, Iris Weinshall.



Michael Kuiken, National Security Adviser, Senator Schumer’s Office

Michael Kuiken currently serves as the National Security Advisor to the Senate Democratic Leader, Senator Chuck Schumer. In this capacity, Mike serves as Senator Schumer’s primary advisor on all national security policy matters and primary liaison to the Department of Defense, Intelligence Community, and National Security Council. He is also Senator Schumer’s ex officio staff member to the Senate Select Committee on Intelligence, and is responsible for all “Gang of 8” intelligence matters.

During his time in Leader Schumer’s office, Mike played a central role in drafting the Countering America’s Adversaries Through Sanctions Act, Endless Frontier Act, and securing the passage of key defense and intelligence authorization acts. He also supports Democratic caucus outreach and management, confirmation of Defense Department, State Department, and Intelligence Community nominees, and formulation of Senate national security policy and legislative priorities.



Jon Cardinal, Director of Economic Development, Senator Schumer’s Office

Jon Cardinal is Director of Economic Development for United States Senate Democratic Leader Charles E. Schumer. In this capacity, he works on the Senator’s legislative agenda on various economic and community development policy areas. Jon previously served in a similar role for more than a decade with United States Senator Kirsten Gillibrand. He began his career on Capitol Hill in 2007 working for former United States Senator Hillary Rodham Clinton.

9:45 –10:15 New York State’s \$620 Million Life Science Initiative And What The Endless Frontier Act Could Mean For New York



Eric Gertler, Empire State Development President CEO and Commissioner

Eric Gertler currently serves as President & CEO-designate of Empire State Development (ESD), New York State’s economic development agency. He was nominated to this position by Governor Andrew M. Cuomo in August 2019. Gertler brings extensive private and public sector leadership to Empire State Development, from roles including Executive Chairman of U.S. News & World Report, managing member of Ulysses Ventures, Executive Vice President of the New York City Economic Development Corporation and Managing Director of the Center for Economic Transformation. A media executive, entrepreneur and published author, Gertler has written and spoken extensively on key policy issues and economic development priorities including workforce development, infrastructure investment, entrepreneurship and innovation. As Executive Chairman of U.S. News



& World Report, the nation's leading news authority on rankings and expert guidance on life decisions, Gertler has provided oversight and overall strategic management and development of the media company. Gertler has also overseen Ulysses Ventures, a New York City based investment fund.

10:15 – 10:45 Life Sci NYC: The Latest Report



Doug Thiede, Senior Vice President, Life Sciences & Healthcare, NYCEDC

Doug Thiede is Senior Vice President of Life Sciences & Healthcare at NYCEDC. Prior to joining NYCEDC, Doug worked exclusively with life sciences companies using software and technology services to address critical business issues. For over fifteen years, Doug has worked with leading life sciences organizations to help launch products, solve challenges, and scale businesses. Doug started his career in life sciences at Aventis Pharmaceuticals, followed by working in the medical device industry, employed by emerging device firms such as Spinal Concepts, Leica Microsystems, and Confluent Surgical. In 2009, Doug moved to New York City to help launch Gerson Lehrman Group's life sciences business. He is a graduate of the University of Virginia.

10:45 – 11:15 Moderated Roundtable Discussion And Audience Q&A

11:15 – 11:30 Break

11:30-12:30 What's New In NYC Life Science Development?



Alexander Karnal, Partner, Deerfield Management Company

Alexander (Alex) Karnal is a Partner and Managing Director at Deerfield and joined the Firm in 2005. He is responsible for portfolio decisions across the Deerfield Funds. Beyond his direct investment activities at the firm, Mr. Karnal helped conceptualize and implement the Cure, Deerfield's healthcare innovation campus at 345 Park Avenue South. Furthermore, during the COVID-19 global health crisis, Mr. Karnal was appointed by Governor Ned Lamont to the Reopen Connecticut Advisory Group to provide counsel on the reopening of the state's economy, community, and education systems. He is a co-founder, CEO and board chairman of The Institute for Life Changing Medicines, a nonprofit dedicated to saving one million people suffering from life-threatening and devastating diseases around the world with no barriers to access. Mr. Karnal serves on the Boards of the New York Academy of Medicine, Biotechnology Innovation Organization, Recovery Centers of America and Discovery Labs, the latter two for which he is a



co-founder. He is a member of the Massachusetts Institute of Technology's corporate development committee, focusing on student life initiatives. Prior to Deerfield, he was a member of Merrill Lynch's Global Equity Linked Products Group and of its Capital Markets team. Mr. Karnal was featured in the April 2020 edition of "The 20 under 40: Inside the next generation of biopharma leaders – Endpoints News." He holds a B.S. in Finance from the Massachusetts Institute of Technology and M.S. in Biotechnology from Johns Hopkins University.



Rob Albro, Managing Director, King Street Properties

As Managing Director at King Street, Mr. Albro has a broad range of responsibilities including acquisitions, dispositions, development, and asset management. Prior to King Street, Mr. Albro most recently served as a Senior Vice President at Beacon Capital Partners, with responsibility for acquisitions and dispositions as well as asset management of the Boston region.



Nolan English, Director of Community and U.S. Operations, SOSV

Nolan English is the Director of Community and U.S. Operations at SOSV. Based in New York City, Nolan is responsible for building the global SOSV alumni community, including managing over \$30M in partner perks redeemed by SOSV companies annually, working with SOSV's platform team to develop tools for alumni, and organizing special programming for founders. He also manages SOSV's operations in the U.S (San Francisco & NYC), overseeing program expansion, real estate, platform development, IT & systems, and special projects.

Nolan first joined SOSV as a Program Manager for Food-X in 2014, responsible for the day-to-day operations of the program and portfolio management. Prior to SOSV Nolan worked in Washington DC in the corporate meeting and events industry. Nolan holds a BA in Literature from Bard College.



Matthew Weir, Senior Vice President, Commercial Asset Management, Taconic Investment Partners

Matthew oversees all aspects of Taconic's commercial property portfolio including asset management, marketing and leasing, development, portfolio strategy, property management, and dispositions. Since joining Taconic in 2006, Matt has been responsible for or directly involved in repositioning over 5 million square feet of commercial space. Matthew earned his Master of Science in real estate with a concentration in development from New York University and graduated summa cum laude with a Bachelor of Business Administration in finance from the University of Wisconsin-Milwaukee.



Scott Metzner, Principal, Janus Property Company

Scott Metzner founded Janus in 1989. He was one of the earliest, developers involved in Harlem's current rebirth, matching for-profit development with public policy and community development initiatives and goals. Prior to his New York projects, he was active in national real estate markets and international master-planning and re-zoning of the largest capital markets through leadership positions at Eastdil Realty, Roseland Property Company

and Daiwa Securities America.

He serves on the Executive Committee of the board of Phipps Houses (New York's largest affordable housing developer/owner), is a member on the board of Phipps Neighborhoods and is Co-Chair of the board of the Tenement Museum. He received an MBA from Columbia University and BArch from the University of Maryland.



H. Guy Liebler, President, Simone Healthcare Development

Mr. Liebler has 35 years of experience in the real estate industry. He began his career at Schulman Realty Group in 1978 and became President and Chief Executive Officer in 1987, a position he held until 1992.

Mr. Liebler joined Sony Corporation in 1993, where he led the development of new business platforms for Sony operating groups.

In 1997, Mr. Liebler was elected Chairman of White Plains Hospital, where he had served as a director since 1988. He led a repositioning of the \$350 million annual revenue hospital by developing a cancer treatment center, expanding the maternity program to include a neo-natal intensive care unit, creating an orthopedic institute, and laying the groundwork for a cardiac center. He served as Chairman of the Board for five years and continues to serve White Plains Hospital as a Chairman Emeritus.

12:30 – 1:00 Moderated Roundtable Discussion And Audience Q&A

1:00 – 5:00 Networking, One-To-One Meeting Opportunities, Exhibitor Booths, On Demand Video Library



DAY TWO: OCTOBER 27TH, 2020

9:00 – 9:15 **Welcome And Overview Of The Meeting**
Mitchel W. Simpler, PE, NYC Builds Bio+ Steering Committee, Managing Partner,
Jaros, Baum & Bolles

9:15 – 9:30 **How Is The Life Science Environment Unfolding In NYC? The Developing Subclusters**

Nancy J Kelley, NYC Builds Bio+, Steering Committee, President and CEO, Nancy J Kelley + Associates

9:30 – 10:30 **Creating NYC Life Science Environments: Lessons Learned From The NYC Building And Design Communities**



Moderator: Bill Allan, Senior Vice President and Director, Business Development, Hunter Roberts Construction Group

Bill has dedicated much of his 30 years of construction management experience to the healthcare industry in both the United States and the United Kingdom. As Senior Vice President & Director of Business Development of Hunter Robert Construction Group and a leader in the company's healthcare division, he has managed and delivered many healthcare construction projects for clients such as Northwell Health, South Nassau Communities Hospital, Blythedale Children's Hospital, NewYork-Presbyterian, Mount Sinai Medical Center, Hospital for Special Surgery, and JT Mather Memorial Hospital. Bill is responsible for the delivery of premier construction management services for these clients, as well as, connecting and building future relationships with new clients. He is a skillful communicator and adopts a collaborative approach with all industry partners in order to ensure that clients' needs are met. Bill is a member of the Royal Institute of Chartered Surveyors and is an ASHE Certified Healthcare Construction professional.



Speakers:
Brooks Slocum, Studio Manager, SGA

Brooks has played a pivotal role in the emergence of SGA as one of the leading architecture firms in the Life Science market. His responsibilities are all inclusive: He oversees all New York-based Life Science projects, encompassing new construction, repositioning, master planning and facilitating planning. He



guides the continuing evolution of the firm, with the aim of cementing SGA's position at the forefront of technology. SGA is an award-winning national architecture, interior design, planning, branded environments practice and virtual design and construction firm. Winner of the Fast Company "Most Innovative Companies" award for architecture, The Boston Real Estate Times's 2020 "Architectural Firm of the Year" and Architizer A+ Award winner for "Architecture + BIM". With over 4 million SF of Life Science facilities on the boards at SGA, the strength of Brooks' experienced team is speed to market, problem solving, fast-track public approvals, and a seamless integration of design, development and construction process.



Don Weinreich, Partner, Ennead Architects

Don Weinreich is a Management Partner in Ennead Architects. He graduated from Columbia University with a Bachelor of Arts and earned his Master of Architecture from the Columbia University Graduate School of Architecture, Planning and Preservation. In addition to his project-related responsibilities, Mr. Weinreich is responsible for the office's technology development, leading the implementation of new ways in which architectural computing can be incorporated into and advance the firm's practice. He is a LEED Accredited Professional and a Fellow of the American Institute of Architects.



Matthew Malone, Practice Leader, Associate Principal, Perkins + Will

As Associate Principal and Practice Leader, Matt leads the Perkins and Will New York studio's science and technology team for a variety of research environments and scientific workplace facilities. With more than 20 years of planning and design experience, Matt has hands-on, practical knowledge of the complex facilities required for life sciences that extends to the research, design, and construction administration for many different typologies included in both new construction and adaptive reuse. He is a leader in the NYC life sciences market, working with developers, owners, institutions, and researchers to contribute to the growing demand for this sector. Matt is a licensed architect with a bachelor's in architecture from Syracuse University.



Christopher Horch, Associate Partner, Jaros, Baum & Bolles

Christopher Horch is a leader in JB&B's HVAC Department and in the firm's Life Science Community of Practice, where he develops and integrates engineering solutions that advance collaboration among technology, science and medicine. His experience extends to both commercial and institutional life science projects, including Innolabs, JLABS @ NYC, IFF Innovation Center, New York Structural Biology Center, New York Genome



Center, Memorial Sloan Kettering Cancer Center's cyclotron project, and the Innovation Center at Duke University Kunshan in Kunshan, China. In sync with the eclectic nature of JB&B's practice, Mr. Horch recently completed work on the TWA Hotel, the reimagination of Eero Saarinen's landmark TWA terminal at John F. Kennedy Airport as well as the new One Vanderbilt tower in Midtown.

Mr. Horch earned his Bachelor of Science degree in Mechanical Engineering from Lehigh University and is a licensed Professional Engineer in the State of New York, a LEED Accredited Professional, and a Certified Energy Auditor. He is a member of ASHRAE, a member of the Young Professionals Committee of the New York Building Congress, a member of the NYC Builds Bio+ Life Sciences Committee, and a member of the New York City Mechanical Code Committee. Mr. Horch also serves as an Expert Peer Review Committee member for the Council on Tall Buildings and Urban Habitat (CTBUH).



Joseph Whalen, Senior Vice President, Operation Director, Lendlease

Joseph (Joe) Whalen has 20 years of New York City construction experience. Having started with Lendlease in 2005, he is a leader of the firm's urban life sciences and affordable multi-family housing practices. Earlier in his career at Lendlease, Joe has worked on healthcare projects for some of the City's most reputable medical institutions.

Over the past two decades Joe has managed the construction of several notable projects, including: Taystee Life Science, NY Methodist Ambulatory, 2016 Arthur Avenue, 1880 Boston Road and Winthrop-University Hospital RAC Building, BioMed Realty Chiller House Upgrade, among many others. His projects are notable for their logistical challenges, delivery methods, emphasis on quality, and innovative safety practices.

A LEED Accredited Professional, Joe is a graduate of the University of Albany, where he earned his B.S. degree in Geology. He resides in Newtown, CT with his wife and two children.



Theodora Diamantis, Vice President, Account Manager, Skanska

Theodora Diamantis brings over 25 years of industry experience. Under her leadership, Skanska has successfully delivered high-profile, multi-million dollar projects in the Metro New York area and throughout the country. Theodora's portfolio includes healthcare, higher education, retail, commercial, and state-of-the-art research laboratories. She successfully leads projects that achieve high safety, quality, and financial performance.

Theodora holds a Bachelor of Science from The Catholic University of America in Civil Engineering and Architecture and a Master of Arts in Architecture.



10:30 – 11:00 Moderated Roundtable Discussion And Audience Q&A

11:00 – 11:15 Break

11:15 – 11:45 NYC Life Science Success Stories: Meet The Companies Leading The Way To Building The Nyc Life Science Cluster



Moderator: John R. Pennett, CPA, Partner in Charge of Technology and Life Science Practice, Eisner Amper LLP

John Pennett is the Partner-in-Charge of the Life Sciences Group and Technology Group. He has 30 years of public accounting experience, with a strong emphasis on public and private life science and technology companies. John is a frequent writer and speaker on topics related to issues impacting businesses in the life sciences and technology space. He is the publisher of Catalyst, a magazine focused solely on issues related to life sciences and pharmaceutical companies. John supports entrepreneurial organizations around the country with content and program development, and serves as a mentor to several early-stage companies. John has led the accounting, auditing and strategic advisory work for more than a hundred IPOs, private financing and mergers and acquisitions with an aggregate valuation in excess of \$2 billion. In addition, he has served as the interim lead of the firm's Risk Advisory Practice, leading internal audit, contract compliance and Sarbanes-Oxley implementation and testing. He is deeply involved in the firm's Outsourced Accounting Services practice and the International Services Group. John previously worked as an Audit Partner for an international accounting and consulting firm.

Speakers:



Gaurav Shah, MD, Chief Executive Office & President, Rocket Pharma

Gaurav Shah serves as President and Chief Executive Officer of Rocket Pharma. Prior to this role Gaurav was a Global Program Head in the Cell & Gene Therapies Unit at Novartis, where he had strategic oversight of 12 functions and helped spearhead pivotal trials with CART-19 for patients with leukemia and lymphoma. Earlier roles at Novartis included Global Clinical Program Head for CART-19 and for Biosimilars, and lead physician for Afinitor in several global oncology submissions. Gaurav started his career in industry at ImClone/Eli Lilly as a Medical Director overseeing oncology trials focused on monoclonal antibodies. Gaurav graduated from Harvard College (summa cum laude, Phi Beta Kappa) with a degree in Behavioral Neuroscience. He received his MD from Columbia (AOA), completed his internal



medicine residency at Brigham and Women's Hospital, and hematology/oncology fellowship training at Memorial-Sloan Kettering. After receiving board certification in medical oncology, he served as an Adjunct Assistant Professor of Oncology at Columbia.

Gaurav also has a passion for Indian classical music and has toured extensively including performances at Carnegie Hall and on National Geographic TV, a feature in the Smithsonian, and a 2019 Grammy nomination (Falu's Bazaar).



Shara Ticku, Co-Founder and CEO, C16 Biosciences

Shara Ticku is the CEO and co-founder of C16 Biosciences. C16 Bio uses biotechnology to produce sustainable alternatives to palm oil. Palm oil is the world's most popular vegetable oil, but depends on tropical rainforest deforestation that emits 1.5 gigatons of CO2 annually. C16 Bio's technology uses microbes to produce an oil that looks and functions just like palm oil, but doesn't destroy the planet. Prior to C16, she worked at the United Nations, the Clinton Health Access Initiative, and Goldman Sachs. She holds an MBA from Harvard Business School and a BA/BBA from the University of Texas.



James McCullough, CEO and Thomas McLain, President and Chief Commercial Officer, RenalytixAI

James McCullough has served as the co-founder and Chief Executive Officer of Renalytix AI since its inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. Since 2014, Mr. McCullough has also served as a managing partner of Renwick Capital, LLC, a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.

11:45 – 12:00 MODERATED ROUNDTABLE DISCUSSION AND AUDIENCE Q&A

12:00 – 12:45 Frontier Technologies: A Discussion Highlighting NYC Companies Along The Life Science Continuum And Their Space Needs



Moderator: Carlo Yuvienco, Vice President, Life Sciences, NYCEDC

Carlo Yuvienco, Ph.D. is Vice President of Life Sciences at the New York City Economic Development Corporation. During his tenure with NYCEDC, he was part of the team that developed the LifeSci NYC 10-year initiative and currently remains instrumental to the plan's implementation. His past and current portfolio of life sciences programs includes city capital projects, investments into early stage companies, workforce development programs, land use initiatives, and regional economic development. Prior to his role at NYCEDC, Dr. Yuvienco completed a post-doctoral fellowship at New York University, focusing on the commercialization of drug-delivery technologies. He is the author of numerous publications in the field of protein science and holder of several biotechnology patents. He has also held research positions with Pall Corporation Life Sciences, specializing in medical device R&D. Dr. Yuvienco earned his B.E. in chemical engineering from the Cooper Union and his Ph.D. in biomedical engineering from New York University.

Speakers:



Anthony Johnson, President & CEO, Therapeutics, Kodikaz

Anthony is the President/CEO of Kodikaz Therapeutic Solutions, Inc., a new entrant in the gene therapy arena. Kodikaz recently moved into NYU/Biolabs to develop its novel cell specific gene transfer technology, it's coined Zip-Codes. Prior to starting Kodikaz, Anthony was the President/CEO of Empire Genomics, a pre-eminent oncology genomic molecular diagnostic company. As the founding CEO of Empire he led the business through multiple funding rounds, acquisition, and licensing deals in addition setting business strategy. Anthony also founded Buffalo Biosciences, (BBS) a technology investment and management services firm. At BBS Anthony worked with clients including tech transfer offices, numerous startups in addition to working with the team that founded the New York Genome Center, NYC's multi-institutional hub for genome research. Prior to Buffalo Biosciences he led the stem cell and cell therapy division for IVGN corporation (Life Technologies/ThermoFisher). In this capacity he was responsible for IVGN's participation in the creation of the California Institute for Regenerative Medicine (CIRM), a \$3 Billion dollar bond issuance to support stem cell research. Mr. Johnson holds a Bachelor's Degree from Fisk University located in Nashville, TN and an MBA from Alliance Manchester Business School, Manchester England. He is a Fellow of the Aspen Institute's Health Innovators Fellowship and member of the Aspen Global Leadership Network.



CJ Ener, Chief Operating Officer, Pandemic Response Lab NYC

CJ is trained as a chemical engineer and brings a decade of experience in operations and process development from 3M Company, Target Corporate, and McKinsey & Company.



Laura Katz, Founder and CEO, Helaina

Laura Katz is the passionate founder and CEO of Helaina and an adjunct professor of Food Science and Technology at NYU. Laura is determined to advance women's health and infant nutrition by providing parents an alternative to infant formula that better meets their infants needs. Through biosynthetic engineering and fermentation, Helaina aims to produce bioactive human milk ingredients both nutritionally and functionally superior to traditional bovine infant formula ingredients.



Will Canine, Co-founder, CPO, Opentrons Labworks

Will believes in democratizing biotechnology because of its potential to solve big problems ranging from food security and climate change to mass manufacturing and sustainable architecture. He first became interested in open-source lab automation as a lever for accelerating biological innovation while working at Genspace during his master's degree at NYU's ITP in 2014. Since then, he has been working on Opentrons -- a company that makes affordable, open-source, easy-to-use lab robots for biologists. Today, Opentrons has grown to a team of 200+ people in NYC, and there are more than 2000 labs in 43 of countries using Opentrons robots to accelerate their lab.



Prem Premsrirut, Founder, President and CEO and Founder, Mobilizing Foundation, Mirimus

Dr. Premsrirut is a cofounder and has served as President and CEO of Mirimus, Inc. since 2010. In response to the COVID-19 pandemic, she launched Mirimus Clinical Labs, which performs low-cost saliva-based pooled surveillance testing for COVID-19. In only 6 months, she has built a high-throughput pipeline for screening large populations on regular cadence schedules and created a roadmap for routine testing to schools and businesses reopen and stay open. She has partnered with the Wynn Resorts to establish an onsite laboratory to enable testing prior to large gatherings. Other partners include the NBA, Yale and institutions across the US. Her team



has been able to build capacity for testing over 4 dozen schools routinely and nursing homes with >30 locations across the US, creating safe spaces, while establishing new protocols for rapid onsite testing. Currently, her team is ramping up to enable testing of up to 50,000 individuals daily while partnering with laboratories across the country to help labs retool and ramp up their capacity as well.

12:45 – 1:00 Moderated Roundtable Discussion And Audience Q&A

1:00 – 5:00 Networking, One-To-One Meeting Opportunities, Exhibitor Booths, On Demand Video Library



DAY THREE: OCTOBER 29TH, 2020

9:00 – 9:15

Welcome

Mitchel W. Simpler, Pe, NYC Builds Bio+ Steering Committee, Managing Partner, Jaros, Baum & Bolles

Overview Of The Meeting

Nancy J Kelley, NYC Builds BIO+ Steering Committee, President and CEO, **Nancy J Kelley + Associates**

9:15 – 10:15

The Life Science Innovation Pipeline: Reports From NYC Academic Medical Centers



Moderator: Kevin Davies, Editor at Large, Genetic Engineering & Biotechnology News

Kevin Davies is the founding Executive Editor of [The CRISPR Journal](#). He is celebrating his 30th year in science publishing, a career that began at Nature, followed by the launch of Nature Genetics. He has also served as the Editor-in-Chief of Cell Press and the publisher of Chemical & Engineering

News. In 2017, Kevin received a Guggenheim Foundation fellowship.

Kevin is the author of several books on the genomics revolution, including Cracking the Genome, The \$1,000 Genome, and DNA: The Story of the Genetic Revolution (with James D. Watson & Andrew Berry). His new book, Editing Mankind, will be published by Pegasus Books in September 2020.

Speakers - Academic Medical Centers




Janis Paradiso, MBA, CLP, Director of the Office of Biotechnology and Business Development, Albert Einstein College of Medicine

Janis Paradiso, MBA, CLP serves as the Director of the Office of Biotechnology and Business Development at Albert Einstein College of Medicine. Ms. Paradiso began her career in academic technology transfer, through a nationally competitive apprentice program at the National Technology Transfer Center, over 15 years ago. Prior to joining Einstein in

2007, she worked in the central technology transfer office of The Research Foundation of State University of New York with primary responsibility for managing technology transfer activities related to SUNY's Downstate Medical Center, College of Optometry and Farmingdale State



campuses. In her current role at Einstein, she leads a fantastic team, working with preeminent researchers and clinicians at Einstein and Montefiore to identify inventions, secure intellectual property protection, and establish partnerships and strategic relationships with industry/investment firms/entrepreneurs in order to further develop, advance and commercialize technologies for the public good. Prior to becoming Director, Janis held multiple progressive roles within the technology transfer operation at the College, primarily focused on marketing, licensing and start-up activities.



Erik Lium, PhD, President, Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Health System, Mount Sinai Innovation Partners

Erik Lium, PhD, is the President of Mount Sinai Innovation Partners (MSIP) and Chief Commercial Innovation Officer of the Mount Sinai Health System. Dr. Lium is responsible for advancing Mount Sinai's research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialization of Mount Sinai technologies, and fostering the

development of start-ups to advance promising early-stage technologies.

Under Dr. Lium's leadership and through Mount Sinai's expansive network of industry partnerships, and vast array of innovators in the fields of drugs, devices, diagnostics, and digital health, Mount Sinai has become a globally recognized leader in technology commercialization. Under his leadership, there has been a significant increase in the number of products brought to the patient population, as well as in Mount Sinai's startup activity surrounding unmet needs in healthcare.



Timothy P O'Connor, Executive Vice President, The Rockefeller University

Timothy O'Connor was appointed executive vice president of The Rockefeller University in February 2016. In this role, he oversees most university operations, including research support, technology transfer, facilities, and information technology, as well as finance, investments, human resources, and legal affairs. Working in partnership with the other executive officers, he provides

administrative leadership to the university and represents the president both internally and externally.



Dr. O'Connor joined the university in 2013 as chief of staff and vice president for university strategy, offering high-level support to the president while overseeing the university's day-to-day operations as well as its long-term initiatives, including the construction of the [Stavros Niarchos Foundation-David Rockefeller River Campus](#).

Dr. O'Connor's career has focused on both biomedical research and academic administration. A native of Los Angeles, he majored in biology at the University of California, Berkeley; earned his Ph.D. from the University of Michigan; and worked as a postdoc in Jared Diamond's laboratory at the University of California, Los Angeles. In 1998, he set up his own lab at the City College of New York, and later moved to Weill Cornell Medical College, where he was appointed associate research professor and vice chair in the Department of Genetic Medicine.



Kathleen Metters, Founding CEO and Chair, Scientific Advisory Board, Bridge Medicine

Dr. Kathleen Metters has over 30 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She is currently working as an independent biopharma consultant, as strategic advisor for New York-based Bridge Medicines and as a member of several boards. Recently, Kathleen was President and Chief Executive officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer.

Previously, Kathleen had a 20 year career at Merck & Co., Inc. During her early Merck career, her research focused on the arachidonic acid cascade which resulted in the development of SINGULAIR®, a once-daily oral therapy for asthma and allergic rhinitis. For her work on SINGULAIR®, she was one of the team of scientists who won the Prix Galien Canada 2000 for excellence in innovative research. Kathleen held several posts at Merck and, in 2005, was appointed to senior vice president and head of Worldwide Basic Research. In this role, she had oversight of all research activities at major sites around the globe; across all therapeutic modalities and all therapeutic areas.

Kathleen graduated with a B.S. in biochemistry from the University of Manchester Institute for Science and Technology, and a Ph.D. from Imperial College of Science and Technology in London. She completed post-doctoral training at the Centre National de la Recherche Scientifique in France and at the Clinical Research Institute of Montréal. During her time in Montréal, Kathleen was an Adjunct Professor appointment in the Department of Pharmacology and Therapeutics at McGill University.



Lisa Placanica, PhD, CLP, Senior Managing Director, Center for Technology Licensing at Cornell University, Weill Cornell Medicine,

Dr. Placanica is Senior Managing Director, Center for Technology Licensing at WCM. In this role she is responsible for overseeing WCM’s activities in technology management, marketing, licensing, and outreach to support Cornell’s goals in commercializing technologies, promoting start-ups, and building partnerships.

building partnerships.

Prior to joining WCM in 2020, Dr. Placanica held the position of Managing Director, Business Development and Licensing at Mount Sinai Innovation Partners. In this role she was responsible for managing a team of business development professionals focused on identifying, advancing, and partnering therapeutic technologies developed at the Mount Sinai Health System and acted as deal team lead for closing complex intellectual property transactions. Dr. Placanica also was a Licensing Manager in the Office of Technology Development at Memorial Sloan Kettering Cancer Center where she focused on development and commercialization of cell and gene therapy related inventions and previously was a key member of the Cell Biology research group at Athersys, Inc in Cleveland, Ohio.

Dr. Placanica received her Ph.D. in Pharmacology from Weill Cornell Medical College where she studied the biochemical composition of gamma secretase and its role in Alzheimer’s Disease in the laboratory of Dr. Yueming Li at Memorial Sloan Kettering Cancer Center. She holds a B.A. in Biology from Cornell University where she graduated Magna Cum Laude with Distinction. In 2013, Dr. Placanica became a Certified Licensing Professional.

10:15 – 10:45 Moderated Roundtable Discussion And Audience Q&A

10:45 – 11:00 Break

11:00 – 12:00 The Life Science Innovation Pipeline: Reports From NYC Incubators/Accelerators



Moderator: Alex Philippidis, Senior News Editor, Genetic Engineering & Biotechnology News

Alex specializes in biopharma business news and industry issues for GEN. He joined GEN in 2011 after four years at GenomeWeb, where he covered research institutes and spent three years following biotech economic development as editor of the weekly newsletter BioRegion News. Alex reports a variety of news stories for GEN and Clinical OMICs and compiles

the popular A-Lists series.



Alex previously worked for more than 20 years for various newspapers covering business, science, the Navy, and general-interest news. He has been interviewed and quoted by news outlets, including the New York Times and the BBC. He enjoys solving crossword puzzles, watching classic TV game shows, and traveling with his family.

Speakers - Incubators/ Accelerators:



Stephen Chambers, NY Partner and Managing Director, IndieBio NY

Stephen was one of the founding scientists at Vertex Pharmaceuticals, working on many drug discovery programs, resulting in the FDA approval of Agenerase & Lexiva. He co-founded Abpro Therapeutics, employing synthetic biology and immunology to accelerate antibody discovery and development. Recruited as CEO of SynbiCITE, the Innovation and Knowledge Center for Synthetic Biology in the UK, he oversaw a dramatic growth in the synthetic biology innovation ecosystem with a record number of startups and fundraising in this sector. At the same time, Stephen co-founded Bio-start, the UK's first Life Science accelerator.

Stephen has co-authored over 30 peer-reviewed scientific publications, including *Nature* and *Cell*, and has several patents. He has been featured in *Huffington Post*, *Upstart*, *BioScience*, and is a regular conference speaker and government advisor on Life Science innovation and entrepreneurship.

Stephen has a Ph.D. in Molecular Biology. Recently awarded Royal Society Entrepreneur in Residence at Imperial College London. He is a Member of the Royal Society's Industrial Fellows College and Fellow of the Royal Society of Biology.




Deepak Hegde, Director, Endless Frontier Labs, NYU Stern School of Business

Professor Deepak Hegde is the Founding Director of the [Endless Frontier Labs](#) and leads the [Berkley Center for Entrepreneurship](#) at the NYU Stern School of Business. Dr. Hegde's research studies how entrepreneurs and inventors overcome the challenges associated with commercializing their ideas. His work has been published in journals such as *Science*, *Journal of Finance* and *Management Science*, and featured in outlets such as *Nature*, *Harvard Business Review* and the *Wall Street Journal*. He was named one of the world's best 40 under 40 business school professors by *Poets & Quants* and Thomas Alva Edison Scholar at the US Patent and Trademark Office. Professor Hegde earned his PhD in Business Economics from the University of California, Berkeley.



Nishta Rao, Managing Director, First Republic Bank, BioLabs@NYU

Nishta is currently Managing Director at First Republic Bank where she is responsible for the growth and expansion of the Bank's Life Science vertical. Prior to this, Nishta was Managing Director, BioLabs@NYU Langone where she supported the translation of technologies into commercially viable products and therapies. In addition Nishta has also launched and led Princeton Innovation Center BioLabs (PICb). Nishta served as Senior Director of Scientific Operations at Kadmon, a biotech startup based in New York City that focuses on discovery, development, and commercialization of small molecules and biologics. Nishta, a molecular biologist by training, has scientific experience both in academia and industry. Nishta has also worked at Mt. Sinai Innovation Partners, the technology transfer office at Mt. Sinai as a Business Development Analyst evaluating technologies and developing partnerships aimed towards commercialization of new technologies.



Samuel K. Sia, PhD, Co-Founder, Harlem Biospace

Samuel Sia, a Professor of Biomedical Engineering at Columbia University, has developed novel technologies for point-of-care blood tests, both in an academic and industry setting. He is co-founder of Claros Diagnostics, which garnered European regulatory approval for a prostate-cancer blood test for doctor's offices, and was acquired by OPKO Health (NYSE: OPK). Dr. Sia's work in global health diagnostics has garnered coverage from Nature, Science, JAMA, Washington Post, BBC, NPR, Voice of America, Science News, Popular Science, Chemical and Engineering News, and MIT Technology Review. His lab-on-a-chip device has been tested in Rwanda to collect and analyze blood tests at a patient's bedside to diagnose infectious diseases. He was named by MIT Technology Review as one of the top's world young innovators, and is an inducted fellow of the American Institute for Medical and Biological Engineering. He is founder of Harlem Biospace, a biotech incubator facility in New York City (developed with the NYC mayor's office) that has hosted over 50 biotech companies. He also currently co-directs the entrepreneurship initiative for Columbia School of Engineering and Applied Sciences. Dr. Sia has a B.Sc. in Biochemistry from the University of Alberta, and a Ph.D. in Biophysics (with a HHMI predoctoral fellowship) from Harvard University. Dr. Sia completed a postdoctoral fellowship in Chemistry and Chemical Biology at Harvard University.



Eva B Cramer, PhD, Vice President for Biotechnology and Scientific Affairs, SUNY Downstate Biotechnology Incubator

Eva Cramer, Ph.D., is a Distinguished Service Professor of Cell Biology, Vice President for Biotechnology and Scientific Affairs at SUNY Downstate Medical Center, and President of the Downstate Biotechnology Incubator and BioBAT at the Brooklyn Army Terminal. She received her Ph.D. from Jefferson Medical School and completed her postdoctoral training at the College of Physicians and Surgeons of Columbia University. Dr. Cramer has published numerous research articles and book chapters in the area of inflammation, was awarded a patent, and received grants from Federal and private agencies.

Dr. Cramer has spearheaded efforts to establish the biotechnology industry in Brooklyn. She has raised over \$90 million from City, State, and Federal governments to build the Downstate Biotechnology Incubator and to develop BioBAT at the Brooklyn Army Terminal for biotechnology expansion and manufacturing. In recognition of her work, she received the Leadership in Urban Health Award from the Arthur Ashe Institute for Urban Health, the Partners in Leadership Award from the Research Foundation of the State University of New York, and the Chancellor's Award from the State University of New York. In addition, she has been designated a Distinguished Service Professor, one of the University's highest honors.



Diane Fabel, Director of Operations, Center for Biotechnology, Stony Brook University

Ms. Fabel serves as the Director of Strategy and Operations for the Center for Biotechnology (CfB), a New York State Center for Advanced Technology. The CfB is a nationally recognized Proof-of-Concept Center and Business Accelerator with designations from the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), the Department of Commerce, and New York State. The CfB focuses its expertise and other resources on the discovery, development, and commercialization of university-based biomedical innovations, the facilitation of company formation, strategic industry partnerships, and investment, and on supporting the growth of the biotech sector in New York State.

Ms. Fabel has an M.S. degree in Technology Management from Stony Brook University and is currently pursuing her doctoral degree within the Department of Biomedical Engineering. Her research is focused on biomedical innovation and commercialization strategies.



Alice Chen, PhD, Vice President, Accelerator Life Science Partners

Dr. Alice Chen has been a vice president at Accelerator Life Science Partners (ALSP) since 2017. She initially joined ALSP in 2013 as a principal to support portfolio company operations and to provide executive oversight of preclinical development activities across the portfolio. She is actively involved in sourcing and scientifically evaluating emerging biotechnology investment opportunities and has played an instrumental role in the formation and oversight of several ALSP portfolio companies. Dr. Chen has more than 15 years of research and drug development experience, principally in small molecule therapeutics. Before joining ALSP, she served as a scientific consultant and drug development project leader for several venture-backed biotechnology companies. Prior to that, she served as Director of Technologies at Qwell Pharmaceuticals, a venture-backed biotechnology company developing novel, small-molecule drugs focused on cancer and inflammation. She also contributed to partnership and M&A initiatives. Dr. Chen completed her doctoral training in the laboratory of Dr. Chaitan Khosla at Stanford University where she focused on protein engineering and protein characterization. She holds a Ph.D. in Chemical Engineering from Stanford University and a B.S. degree in Chemical Engineering from U.C. Berkeley. She served as an Engineering Fellow at Merck & Company and is a graduate of the Kauffman Fellows Program (Class 19). Dr. Chen currently serves on the boards of the Evergreen Fund Advisory Committee for the Fred Hutch Cancer Research Center and Life Science Washington, the state's life science trade association.



Cynthia Cleto, Director – Outreach, Entrepreneurship & Special Programs, Mount Sinai Innovation Partners

Cynthia is a commercialization catalyst, and leads the Outreach, Entrepreneurship and Special Programs at Mount Sinai Innovation Partners. She coordinates strategic communications to educate innovators, potential partners and the broader healthcare marketplace about Mount Sinai's leadership in technology development and commercialization. She is a key stakeholder in the branding and positioning of new ventures from Mount Sinai, including Kantaro Biosciences. Her outcomes include an expanded technology pipeline, collaborations and sponsored research as well as revenue resulting from new ventures and economic development initiatives. Prior to Mount Sinai, Cynthia was the Regional Systems Manager for North America within Elsevier's research management and analytics unit. She launched new and innovative software solutions that surface competencies and collaborative opportunities for research intensive institutions. Cynthia also introduced ground-breaking products to the market, including eBook Collections for Springer Science+Business Media, A&I and Chemistry Databases for Elsevier as well as Thieme Medical Publishers. Before entering the STM



Publishing field, Cynthia trained and worked as a lab supervisor and graduate student in genomics laboratories at McGill University, Montreal, Canada.

12:00 – 12:30 Moderated Roundtable Discussion And Audience Q&A

12:30 – 1:00 What Is The Future Promise For Life Sciences? Views From The Investment Community



Closing Keynote: Po Bronson, Managing Director, IndieBio and General Partner, SOSV

Po is Managing Director of IndieBio and General Partner at SOSV, the venture fund behind IndieBio.

IndieBio, originally based out of San Francisco, is the world's # biotech accelerator, having created 136 companies in 5 years, that are now worth over \$3 billion. In 2019, IndieBio was chosen by the state of New York as its life sciences accelerator partner, which opened in Manhattan in March of 2020. Po was a finance and tech journalist covering Silicon Valley for Wired, The New York Times Magazine, and an oped contributor for The Wall Street Journal.

His science journalism has been honored with nine national awards, and he is the author of seven bestselling books that are available in 28 languages worldwide. His work has been cited in 185 academic journals and 503 books. His background is in Economics with specialization in understanding firm behavior in collaborative networks. He learned finance at Credit Suisse and consulting at a division of Arthur Andersen. Prior to IndieBio he spent four years as a Futurist with Attention Span Media, consulting corporate innovation efforts for globally-recognized brands. Most recently, Po is the author of *Decoding the World: A Roadmap for the Questioner*, published by Twelve Books, a division of the Hachette Publishing Group.

Discussion And Audience Q&A

1:00 – 1:15 Wrap Up And Next Steps

1:15 – 5:00 Networking, One-To-One Meeting Opportunities, Exhibitor Booths, On Demand Video Library